SAMYANG
LIVE

Serial Number

79417917

Owner

Samyang Holdings Corporation

Attorney

Richard Y. Kim

Filing Date

Dec 18, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SAMYANG Trademark

Serial Number: 79417917 • Registration: 8208751

SAMYANG is a trademark filed by Samyang Holdings Corporation on December 18, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Samyang Holdings Corporation

31, Jong-ro 33-gil, Jongno-gu

Entity Type: 03

Trademark Details

Filing Date

December 18, 2024

Registration Date

April 14, 2026

Published for Opposition

February 24, 2026

Goods & Services

Pharmaceutical preparations for health care, namely, nutritional supplements; vaccines; food supplements; natural remedy preparations for the treatment of hangover with vitamin B1 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin B2 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin C containing yeast-based ingredients for medical purposes; vitamin and mineral dietary supplements; veterinary substances and preparations, namely, veterinary vaccines; medicinal preparations for the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; filled syringes for medical purposes containing pharmaceuticals in the nature of anti-infectives; antibiotic ointments for pharmaceutical purposes; cachets for pharmaceutical purposes in the nature of pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations being hormone preparations in the nature of preparations for the suppression of hormones for human use; pills for pharmaceutical purposes for the treatment of cancer and prevention of viruses; pills for pharmaceutical purposes, namely, pills for the treatment of viral, bacterial, and fungal infection and immune disorder; ferments for pharmaceutical purposes; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films and coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of respiratory diseases; pre-filled syringes for medical purposes sold filled with pharmaceuticals for skin care, skin regeneration, skin moisturization, aesthetic treatments, and hyaluronic acids, Botulinum toxin, and pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; pharmaceutical preparations for skin care, namely, skin anti-aging preparations for medical use; pharmaceuticals preparation, namely, pharmaceutical fillers in the nature of injectable dermal fillers, bone fillers consisting of living materials, bone void fillers consisting of natural materials for medical use; pharmaceutical syringes prefilled with medical hyaluronic acid as the main ingredient; medicinal drinks; pharmaceutical drugs, namely, antipyretics, anti-infectives, antineoplastics, diuretics, and pharmaceutical preparations for the treatment of immune system disorders, disorders of the central nervous system, endocrine disorders, gastrointestinal diseases, dermatological diseases, infectious diseases, cardiovascular diseases, and respiratory diseases; medicinal infusions for treating dermatological, kidney, heart, urological, and circulatory diseases, as well as cancer and inflammatory conditions; pharmaceuticals, namely, antivirals; pharmaceuticals, namely, pharmaceuticals for the treatment of cancer; human vaccine preparations; medicines for human purposes for dental purposes; medicines for human purposes for the treatment of cardiovascular and cerebrovascular diseases; medicines for human purposes for the treatment of cancer; medicines for human purposes for the treatment and prevention of iron deficiency and anemia; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for wrinkle treatment; injectable pharmaceutical preparations in the nature of injectable dermal fillers for filling wrinkle in the form of gel; injectable dermal fillers; implantable medicines for the prevention and treatment of diabetes; implantable medicines for the prevention and treatment of cardiovascular diseases; implantable medicines for the prevention and treatment of central nervous system diseases; implantable medicines for the prevention and treatment of cancer; implantable medicines for the prevention and treatment of metabolism diseases; nutraceutical preparations for therapeutic and medical purposes, namely, nutraceuticals for the treatment of cancer, diabetes, and headaches; dermatological pharmaceutical products; gels, creams and solutions for dermatological use; pharmaceutical preparations for use in dermatology, namely, injectable dermal fillers; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin whitening; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin care, namely, injectable pharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin care; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin regeneration; antibiotics; nicotine patches for use as aids to stop smoking; pharmaceutical preparations used in the smoking cessation, namely, smoking cessation preparations; anti-adhesion agents for medical purposes, namely, anti-adhesion gels for use with wound drainage devices; surgical glues; denture adhesives; dental adhesives; medical adhesives for binding internal tissue; medical adhesives for binding wounds; hemostatics for medical purposes; transdermal patches for medical treatment for use in the treatment of psoriasis, acne, fungal infection, and skin disorders; anti-cancer preparations

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 27, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 26, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 14, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 14, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 14, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 24, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 24, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 18, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 29, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 29, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 29, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 29, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 29, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 23, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 2, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 2, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 12, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 11, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 21, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 21, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 27, 2025 REPR